What is the 13F Pro Quality Score for VMD?

13F Pro ranks VIEMED HEALTHCARE, INC. (VMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VMD's current score at https://13fpro.ai/research/VMD (free sign-up required for the full ranking).

Which hedge funds own the most VMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VMD include BlackRock,, Forager Capital Management,, GOLDMAN SACHS GROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VMD as soon as new 13F filings post.

Where does 13F Pro source VMD data?

All VIEMED HEALTHCARE, INC. fundamentals and ownership data come directly from SEC EDGAR. VIEMED HEALTHCARE, INC. files with the SEC under CIK 1729149. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VMD in?

VIEMED HEALTHCARE, INC. (VMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VMD research updated on 13F Pro?

VMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VIEMED HEALTHCARE, INC.(VMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1729149 VMD stock profile & AI dashboard →

13F Pro Quality Score

57.2/100

Rank #1,062 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.8/100

Profitability

51.8/100

Balance Sheet

74.9/100

Earnings Quality

67.7/100

Free Cash Flow

37.9/100

Institutional Flow

87.5/100

Revenue Scale

27.9/100

Dilution Risk

31.7/100

VMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VIEMED HEALTHCARE, INC. (VMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VMD at 57.2/100 on a 32-signal composite quality model, placing it at rank #1,062 of 2,879 stocks — the top half of the AI-ranked universe. VMD scores in the top quartile across institutional flow (87.5), revenue growth (81.8). Areas of concern include revenue scale (27.9) and free cash flow (37.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), VIEMED HEALTHCARE, INC. reports quarterly revenue of $75.4M, net income of $2.6M, an operating margin of 5.7%. Top institutional holders of VMD by reported 13-F value include BlackRock,, Forager Capital Management,, GOLDMAN SACHS GROUP, based on the most recent SEC filings. VMD trades on the Nasdaq exchange and files with the SEC under CIK 1729149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VIEMED HEALTHCARE, INC. directly from SEC EDGAR. VIEMED HEALTHCARE, INC.'s 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 57.2 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$75.4M

Net Income

Q1 2026

$2.6M

Free Cash Flow

Q1 2026

$1.4M

Operating Margin

Q1 2026

5.7%

D/E Ratio

Q1 2026

0.06

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+22.5% YoY

$224.3MFY 2024

FY20 $131.3MFY21 $117.1MFY23 $183.0MFY24 $224.3M

Net Income

+10.0% YoY

$11.3MFY 2024

FY20 $31.5MFY21 $9.1MFY23 $10.2MFY24 $11.3M

Operating Income

+24.9% YoY

$17.9MFY 2024

FY20 $26.8MFY21 $11.6MFY23 $14.3MFY24 $17.9M

EPS (Diluted)

+12.0% YoY

$0.28FY 2024

FY20 $0.78FY21 $0.22FY23 $0.25FY24 $0.28

Total Assets

+14.3% YoY

$177.1MFY 2024

FY20 $112.6MFY21 $118.0MFY23 $154.9MFY24 $177.1M

Total Debt

-43.5% YoY

$4.0MFY 2024

FY20 $7.6MFY21 $5.8MFY23 $7.1MFY24 $4.0M

Op. Cash Flow

-13.5% YoY

$39.1MFY 2024

FY20 $35.1MFY21 $22.5MFY23 $45.2MFY24 $39.1M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$224.3M +22.5%	$183.0M +56.3%	$117.1M -10.8%	$131.3M +63.6%	$80.3M	—
Net Income	$11.3M +10.0%	$10.2M +12.2%	$9.1M -71.1%	$31.5M +269.9%	$8.5M	—
Operating Income	$17.9M +24.9%	$14.3M +23.7%	$11.6M -56.8%	$26.8M +202.4%	$8.9M	—
EPS (Diluted)	$0.28 +12.0%	$0.25 +13.6%	$0.22 -71.8%	$0.78 +271.4%	$0.21	—
Total Assets	$177.1M +14.3%	$154.9M +31.3%	$118.0M +4.8%	$112.6M +36.3%	$82.6M	—
Total Debt	$4.0M -43.5%	$7.1M +22.3%	$5.8M -24.2%	$7.6M -18.6%	$9.4M	—
Operating Cash Flow	$39.1M -13.5%	$45.2M +101.0%	$22.5M -35.9%	$35.1M +83.9%	$19.1M	—

AI Insight: VMD Financial Trends

Revenue growth accelerated to 31% year-over-year in Q4 2025, but operating performance weakened significantly in Q1 2026.

• Revenue expanded from $55M in Q2 2024 to $75M in Q1 2026, with strongest growth in Q4 2025.

• Operating cash flow improved from $10M in Q2 2024 to $18M in Q4 2025 before declining to $8M in Q1 2026.

• Total debt increased from $4M in Q4 2024 to $21M in Q3 2025 before moderating to $9M in Q1 2026.

⚠ Operating income dropped 50% from $8M in Q4 2025 to $4M in Q1 2026 despite revenue remaining elevated.

⚠ Operating cash flow fell 56% quarter-over-quarter to $8M in Q1 2026, the weakest level since Q2 2024.

AI Insight: VMD Ratio Trends

VMD exhibits strong Q4 performance but concerning Q1 2026 deterioration with operating margin falling to 5.7% from 11.0% peak.

• Operating margin peaked at 11.0% in Q4 2025 but dropped sharply to 5.7% in Q1 2026.

• ROIC declined from 21.8% in Q4 2025 to 11.2% in Q1 2026, erasing prior gains.

• Debt-to-equity ratio remains low at 0.06, down from 0.08 in Q2 2024.

⚠ Q1 2026 marks second consecutive quarter of margin compression after Q4 2025 peak.

⚠ ROA volatility ranges from 3.6% to 11.3% across periods, suggesting operational inconsistency.

Get alerted when VMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VIEMED HEALTHCARE, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VMD

BlackRock, Inc.
$42.6M4,622,562 sh
Forager Capital Management, LLC
$26.0M2,825,871 sh
GOLDMAN SACHS GROUP INC
$13.1M1,421,634 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.0M1,303,384 sh
AMERIPRISE FINANCIAL INC
$8.3M898,319 sh
Nantahala Capital Management, LLC
$8.1M883,783 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.2M779,522 sh
STATE STREET CORP
$6.8M742,959 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$6.6M711,186 sh
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$4.9M537,361 sh

Fund	Value	Shares
BlackRock, Inc.	$42.6M	4,622,562
Forager Capital Management, LLC	$26.0M	2,825,871
GOLDMAN SACHS GROUP INC	$13.1M	1,421,634
VANGUARD CAPITAL MANAGEMENT LLC	$12.0M	1,303,384
AMERIPRISE FINANCIAL INC	$8.3M	898,319
Nantahala Capital Management, LLC	$8.1M	883,783
GEODE CAPITAL MANAGEMENT, LLC	$7.2M	779,522
STATE STREET CORP	$6.8M	742,959
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$6.6M	711,186
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	$4.9M	537,361

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VMD on your watchlist

Track score changes the day VIEMED HEALTHCARE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VMD a good stock to buy?

13F Pro's AI-powered analysis of VIEMED HEALTHCARE, INC. (VMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VMD are available on the VMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VIEMED HEALTHCARE, INC.'s investment landscape.